Viewing StudyNCT06254690



Ignite Creation Date: 2024-05-06 @ 8:06 PM
Last Modification Date: 2024-10-26 @ 3:20 PM
Study NCT ID: NCT06254690
Status: RECRUITING
Last Update Posted: 2024-02-12
First Post: 2024-01-28

Brief Title: The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer a Phase II Clinical Study
Sponsor:
Organization: The First Affiliated Hospital with Nanjing Medical University